Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access February 13, 2014

Interaction between Levothyroxine and Phenprocoumon: a case report

  • Walderez Gaeti EMAIL logo , Paulo Obreli-Neto and Roberto Cuman
From the journal Open Medicine


Several case reports have associated the combined use of thyroid drugs and oral anticoagulants, like coumarin, with overanticoagulation. However, this effect has never been described for phenprocoumon, a coumarin derivate that is widely prescribed in continental European countries and in Latin America. We describe a 62-year-old female who had an unexpectedly labile anticoagulation profile when levothyroxine (Puran T4®) was added to her drug therapy regimen, which included phenprocoumon (Marcoumar®). This resulted in an elevated international normalized ratio (INR) that was unrecordable and bleeding (macroscopic hematuria) that required hospitalization and treatment with vitamin K. The patient had been taking phenprocoumon for almost ten years for systemic embolism prophylaxis because of her history of mechanical bileaflet mitral valve prosthesis. One month before the events described, the patient was prescribed sodium levothyroxine (50 mcg daily) to treat hypothyroidism (TSH = 40 µU/mL; reference range, 0.40–4.0 µU/mL). Approximately 3 weeks prior to initiation of levothyroxine treatment, her INR was 2.8. A drug interaction was therefore suspected. The Horn Drug Interaction Probability Scale (DIPS) indicated a probable interaction between oral phenprocoumon and levothyroxine in this case. Clinicians should be aware that levothyroxine may interact with oral phenprocoumon, resulting in overanticoagulation.

[1] Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002;117:940–946 in Google Scholar PubMed

[2] Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S–198S in Google Scholar PubMed

[3] Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008;100:1052–1057 10.1160/TH08-04-0116Search in Google Scholar

[4] Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 2010;66:253–260 in Google Scholar PubMed

[5] Leiria TL, Pellanda L, Miglioranza MH, Sant’anna RT, Becker LS, Magalhães E, et al. Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic. Arq Bras Cardiol 2010;94:41–45 in Google Scholar

[6] Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S–21S in Google Scholar

[7] Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004;60:173–182 in Google Scholar PubMed

[8] Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44:1227–1246 in Google Scholar PubMed

[9] Gavronski M, Hartikainen S, Zharkivsky A. Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more. Pharmacy Practice 2012;10:9–16 10.4321/S1886-36552012000100003Search in Google Scholar

[10] Brunton L, Parker K, Blumenthal D, Buxton I. Goodman & Gilman. Manual of Pharmacology and Therapeutics. New York: The McGraw-Hill Companies, 2008 Search in Google Scholar

[11] British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Publishing Group, 2009 Search in Google Scholar

[12] Drug interactions between coumadin and levothyroxine from Available from: Accessed: 2011 October Search in Google Scholar

[13] Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674–680 in Google Scholar PubMed

[14] Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf 1994;10:381–394 in Google Scholar

[15] Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Engl J Med. 1962;266:76–79 in Google Scholar

[16] Bubber P, Bubber N, Bansal DD. Effect of thyroxine on plasminogen activator and inhibitor activity in rat. Indian J Exp Biol 2009;47:147–150 Search in Google Scholar

[17] Negrev N, Tashev R, Radev R, Anogeianaki A, Ivanova M. Hormones of hypothalamic-pituitarythyroid axis are significant regulators of synthesis and secretion of vitamin K-dependent plasma coagulation factors. J Biol Regul Homeost Agents 2011;25:21–26 Search in Google Scholar

[18] Walters MB. The relationship between thyroid function and anticoagulant therapy. Am J Cardiol 1963;11:112–114 in Google Scholar

[19] Food and Drug Administration. Unithroid (levothyroxine sodium tablets, USP). Available from: Accessed: 2011 October Search in Google Scholar

[20] Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30:416–444 in Google Scholar PubMed

Published Online: 2014-2-13
Published in Print: 2014-4-1

© 2014 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 23.3.2023 from
Scroll Up Arrow